If what you suggest is a possibility, I would view the early December "Investor's Day" in hindsight as more of a dog and pony show for potential buyers. At this point, investors have been beaten to the point that most of us would accept if the company was sold for $6 or $7 a share. What would that be, $2 billion to $3 billion? Even if peak sales only reached $1 billion annually, the buyer would get a great payout. It has to look good to a buyer that Amarin has locked up half the European population as potential customers, along with China, Canada and other revenue streams. It probably makes sense to sell the company for whatever can be gotten in the next year while there is still a long runway on the European patents. If a sale seems likely in the short haul, that also might explain why they never executed the share buyback and why they don't seem overly panicked about the potential NASDAQ delisting.